Literature DB >> 10853802

The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.

K Brandt-Mainz1, S P Müller, R Görges, B Saller, A Bockisch.   

Abstract

The early detection of metastases from medullary thyroid cancer (MTC) is important because the only curative therapy consists in surgical removal of all tumour tissue. There is no single sensitive diagnostic imaging modality for the localization of all metastases in patients with MTC. Therefore, in many cases several imaging modalities (e.g. ultrasonography, magnetic resonance imaging, computerized tomography and scintigraphy using pentavalent technetium-99m dimercaptosuccinic acid, thallium-201 chloride, indium-111 pentetreotide, anti-CEA antibodies or metaiodobenzylguanidine) must be performed consecutively in patients with elevated calcitonin levels until the tumour is localized. In this prospective study, we investigated the value of fluorine-18 fluorodeoxyglucose positron emission tomography ([18F]FDG PET) in the follow-up of patients with MTC. [18F]FDG PET examinations of the neck and the chest were performed in 20 patients with elevated calcitonin levels or sonographic abnormalities in the neck. Positive [18F]FDG findings were validated by histology, computerized tomography or selective venous catheterization. [18F]FDG PET detected tumour in 13/17 patients (nine cases were validated by histology, four by computerized tomography). Five patients showed completely negative PET scans (of these cases, one was true-negative and four false-negative). One patient with [18F]FDG accumulation in pulmonary lesions from silicosis and one patient with a neck lesion that was not subjected to histological validation had to be excluded. Considering all validated localizations, [18F]FDG PET detected 12/14 tumour manifestations in the neck, 6/7 mediastinal metastases, 2/2 pulmonary metastases and 2/2 bone metastases. In two patients with elevated calcitonin levels, no diagnostic modality was able to localize a tumour. The sensitivity of [18F]FDG PET in the follow-up of MTC was 76% (95% confidence interval 53%-94%); this is encouraging. [18F]FDG PET promises to be a valuable diagnostic method, especially for the detection of lymph node metastases, surgical resection of which can result in complete remission.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10853802     DOI: 10.1007/s002590050533

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  17 in total

1.  Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma.

Authors:  Martin Gotthardt; Martin P Béhé; Daniela Beuter; Anke Battmann; Artur Bauhofer; Tino Schurrat; Meike Schipper; Halina Pollum; Wim J G Oyen; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-11       Impact factor: 9.236

2.  Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT.

Authors:  Andrei Iagaru; Rinat Masamed; Peter A Singer; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

3.  Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.

Authors:  B Beuthien-Baumann; A Strumpf; J Zessin; J Bredow; J Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-14       Impact factor: 9.236

4.  Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.

Authors:  Giorgio Treglia; Paola Castaldi; Maria Felicia Villani; Germano Perotti; Chiara de Waure; Angelina Filice; Valentina Ambrosini; Nadia Cremonini; Monica Santimaria; Annibale Versari; Stefano Fanti; Alessandro Giordano; Vittoria Rufini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-06       Impact factor: 9.236

Review 5.  Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis.

Authors:  Giorgio Treglia; Maria Felicia Villani; Alessandro Giordano; Vittoria Rufini
Journal:  Endocrine       Date:  2012-04-17       Impact factor: 3.633

6.  Medullary thyroid carcinoma with micronodular lung metastases: a case report with an emphasis on the imaging findings.

Authors:  Nina Ventura; Edson Marchiori; Gláucia Zanetti; Antonio Muccillo; Mariana Leite Pereira; Guilherme Abdalla; Pedro Martins; Carolina Lamas Constantino; Rodrigo Canellas; Viviane Brandão; Romulo Varella de Oliveira
Journal:  Case Rep Med       Date:  2010-05-17

7.  Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.

Authors:  Rafał Czepczyński; Maria Gemma Parisella; Jerzy Kosowicz; Renata Mikołajczak; Katarzyna Ziemnicka; Maria Gryczyńska; Jerzy Sowiński; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-26       Impact factor: 9.236

8.  Calcitonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease: a descriptive analysis.

Authors:  I Vainas; A Marthopoulos; A Chrisoulidou; K Raptou; K Tziomalos; K Pazaitou-Panayiotou
Journal:  Hippokratia       Date:  2013-07       Impact factor: 0.471

9.  The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.

Authors:  Mohsen Beheshti; Sigrid Pöcher; Reza Vali; Peter Waldenberger; Gabriele Broinger; Michael Nader; Susanne Kohlfürst; Christian Pirich; Henning Dralle; Werner Langsteger
Journal:  Eur Radiol       Date:  2009-01-21       Impact factor: 5.315

10.  PET Imaging in Recurrent Medullary Thyroid Carcinoma.

Authors:  Giorgio Treglia; Vittoria Rufini; Massimo Salvatori; Alessandro Giordano; Luca Giovanella
Journal:  Int J Mol Imaging       Date:  2012-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.